All In Biotech

Drug Trial Radar · NCT06151964

A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD9550 Monotherapy and Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity and Overweight With or Without Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 166 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

166

Actual

Start

Sep 29, 2023

Primary completion

Jan 29, 2027

Study completion Jan 29, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AZD9550, previously being developed for the treatment NASH, is a dual GCG and GLP-1 receptor agonist. AZD9550 is now being developed in combination with AZD6234, a SARA, for the treatment of overweight and obesity and its associated co-morbidities. Co-administration of AZD9550 and AZD6234 is currently being evaluated in participants living with obesity and overweight without T2DM in an ongoing Phase 2b study. The purpose of this study is to investigate the safety, tolerability, and effects of increasing doses of AZD9550 monotherapy in overweight and obese participants aged 18 through 65 years living with or without T2DM, and to investigate how AZD9550 is absorbed, distributed, and eliminated from the body (Parts A-D). In addition, the study will investigate the safety and tolerability of co-administration of AZD9550 and AZD6234 in participants living with T2DM with obesity or overweight aged 18 through 75 years (Part E), and safety and tolerability for different titration regimens for AZD9550 in participants living with obesity, but without T2DM, aged 18 through 75 years (Part F).

Conditions

  • Overweight and Obesity

Interventions

  • AZD9550Drug

    Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part F: Doses of AZD9550 that increase every 4 weeks or every 2 weeks and then every 4 weeks

  • placeboDrug

    Matching administration volumes for SC injection. For Part E placebo two injections of two different placebos.

  • AZD9550 and AZD6234Drug

    Part E: Doses of AZD9550 and AZD6234 that increase every 2 weeks, then every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and percentage of participants with any AE, SAEs, AEs leading to discontinuation of study intervention, AEs with outcome of death, and AEs leading to withdrawal from study.Time frame: Day - 35 to Day 261
  2. Number and percentage of participants with clinically significant changes from baseline in Vital Sign Parameters.Time frame: Day - 35 to Day 261
  3. Number and percentage of participants with clinically significant changes in ECG parameters.Time frame: Day - 35 to Day 261
  4. Number and percentage of participants with clinically significant changes from baseline in Clinical Laboratory ParametersTime frame: Day - 35 to Day 261
  5. Area Under Concentration-Time Curve of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
  6. Maximum observed concentration of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
  7. Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
  8. Time to maximum observed concentration of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
  9. Apparent oral clearance of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
  10. Apparent volume of distribution of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
  11. Ratio for AUC of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
  12. Ratio for Cmax of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65

Locations

15 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    Graz, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Surrey, British Columbia, Canada

  • Research Site

    Hamilton, Ontario, Canada

  • Research Site

    Sarnia, Ontario, Canada

  • Research Site

    Stouffville, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Sherbrooke, Quebec, Canada

  • Research Site

    Magdeburg, Germany

  • Research Site

    Neu-Ulm, Germany

  • Research Site

    Neuss, Germany

  • Research Site

    Fukuoka, Japan

  • Research Site

    Shinjuku-ku, Japan

  • Research Site

    Suita-shi, Japan

  • Research Site

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.